Teva Pharmaceutical Industries (TEVA) Q4 2023 Earnings Call Transcript
https://seekingalpha.com/article/4666377-teva-pharmaceutical-industries-teva-q4-2023-earnings-call-transcript?source=feed_tag_israel
Jan 31, 2024 - Teva Pharmaceutical Industries Limited (NYSE:NYSE:TEVA) Q4 2023 Earnings Conference Call January 31, 2024 8:00 AM ETCompany ParticipantsRichard Francis -...
0
Teva Pharmaceutical Non-GAAP EPS of $1.00 beats by $0.24, revenue of $4.46B beats by $450M
https://seekingalpha.com/news/4060531-teva-pharmaceutical-non-gaap-eps-of-1_00-beats-0_24-revenue-of-4_46b-beats-450m?source=feed_tag_israel
Jan 31, 2024 - Teva Pharmaceutical reports strong Q4 earnings, exceeding expectations.
0
Teva hits 52-week high on outlook, API divestment
https://seekingalpha.com/news/4060755-teva-stock-hits-52-week-high-outlook?source=feed_tag_israel
Jan 31, 2024 - Teva Pharmaceutical (TEVA) reached a new 52-week high after beating Q4 2023 forecasts and announcing plans to divest its API business. Read more here.
0
Teva earnings preview: Israeli drugmaker to report early Wednesday
https://seekingalpha.com/news/4060267-teva-earnings-preview-israeli-drugmaker-to-report-early-wednesday?source=feed_tag_israel
Jan 30, 2024 - Teva Pharmaceutical Industries (TEVA) is expected to report higher Q4 earnings before market open on Wednesday, with investors looking to see if the Israeli dru
0
Teva to divest API unit to focus on core business strengths
https://seekingalpha.com/news/4060502-teva-to-divest-api-unit-to-focus-on-core-business-strengths?source=feed_tag_israel
Jan 31, 2024 - Teva plans to divest its API business as part of its growth strategy, aiming to focus on core strengths and capitalize on opportunities in the global API...
0
Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
https://seekingalpha.com/article/4673481-teva-alvotech-simlandi-approval-opens-new-generic-market-opportunities?source=feed_tag_israel
Feb 26, 2024 - Teva's stock has risen 32% since December, outperforming the SPY, buoyed by FDA approval of Simlandi, a biosimilar to Humira. Learn more about TEVA stock here.
0
Teva upgraded at J.P. Morgan on upcoming catalysts
https://seekingalpha.com/news/4077679-teva-stock-upgraded-jp-morgan-catalysts?source=feed_tag_israel
Mar 08, 2024 - Teva Pharmaceutical (TEVA) receives an upgrade from J.P. Morgan, on upcoming positive catalysts as the bank reviews its specialty pharma coverage. Read more here.
0
Teva and mAbxience sign global licensing agreement for oncology biosimilar candidate
https://seekingalpha.com/news/4087243-teva-and-mabxience-sign-global-licensing-agreement-for-oncology-biosimilar-candidate?source=feed_tag_israel
Apr 04, 2024 - Teva Pharmaceuticals and mAbxience have signed a strategic licensing agreement to develop a biosimilar treatment for multiple oncology indications,...
0
Alvotech/Teva bring new partner to expand access for Humira biosimilar in U.S.
https://seekingalpha.com/news/4091382-alvotech-signs-u-s-agreement-to-expand-access-for-newly-approved-high-concentration?source=feed_sector_healthcare
Apr 19, 2024 - Alvotech (ALVO) in agreement with Teva Pharmaceuticals (TEVA), signed a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryv in US market.
0
FTC challenges 'junk' patents held by 10 drugmakers, including for Novo Nordisk's Ozempic
https://www.cnbc.com/2024/04/30/ftc-challenges-patents-held-by-drugmakers-including-for-ozempic.html
Apr 30, 2024 - The agency sent letters to Novo Nordisk, AstraZeneca, Boehringer Ingelheim, Covis Pharma, GlaxoSmithKline, Novartis, Teva Pharmaceuticals, among others.
0